A61K

(21) Int. Application Number: PCT/EP97/02504
(22) Int. Filing Date: 12 May 1997 (12.05.97)
(30) Priority Data: 96201429.6 20 May 1996 (20.05.96) EP
(34) Countries for which the regional or international application was filed: DE et al.
(51) International Patent Classification 6: A61K 31/505
A1
(11) Int. Publication Number: WO 97/44039
(43) Int. Publication Date: 27 November 1997 (27.11.97)

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
(72) Inventors; and
(75) Inventors/Applicants (for US only): FRANÇOIS, Marc, Karel, Jozef [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE); EMBRECHTS, Roger, Carolus, Augusta [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE); BORGHIJS, Herman, Karel [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE); MONBALIU, Johan [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS

(57) Abstract

The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.

(21) Int. Application Number: PCT/EP97/02710
(22) Int. Filing Date: 15 May 1997 (15.05.97)
(30) Priority Data: 96201450.2 23 May 1996 (23.05.96) EP
(34) Countries for which the regional or international application was filed: DE et al.
(51) International Patent Classification 6: A61K 31/505, C07D 471/04
A1
(11) Int. Publication Number: WO 97/44040
(43) Int. Publication Date: 27 November 1997 (27.11.97)

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
(72) Inventors; and
(75) Inventors/Applicants (for US only): KENNIS, Ludo, Edmond, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). MERTENS, Josephus, Carolus [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).
(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: HEXAHYDRO-PYRIDO(4,3-B)INDOLE DERIVATIVES AS ANTIPSYCHOTIC DRUGS

(57) Abstract

This invention concerns the compounds of formula (I), the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C_{1-6}alkanediyl; R^1 is hydrogen, C_{1-6}alkyl, aryl or arylC_{1-6}alkyl; R^2, R^3 and R^4 are each independently selected from hydrogen, halo, hydroxy, nitro, cyano, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, C_{1-6}alkylthio, mercapto, amino, mono- and di(C_{1-6}alkyl)amino, carboxyl, C_{1-6}alkyloxycarbonyl or C_{1-6}alkylcarbonyl; R^5 is hydrogen, C_{1-6}alkyl, phenyl or phenylC_{1-6}alkyl; R^6 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, or a radical of formula $-NR^8R^9$, wherein R^8 and R^9 are each independently selected from hydrogen, C_{1-6}alkyl, phenyl or phenylC_{1-6}alkyl; R^7 is hydrogen or C_{1-6}alkyl; or R^6 and R^7 taken together may form a bivalent radical of formula $-R^6-R^7-$; having central dopamine and serotonin antagonistic activity; their preparation, compositions containing them and their use as a medecine.


(I)